Latest news
RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy - BioPharma APACBioPharma APAC · Sun, 09 Aug 2026 18:30:13 GMTDoes Patient Selection Inflate CAR T Outcomes in Multiple Myeloma? - CancerNetworkCancerNetwork · Sun, 09 Aug 2026 16:10:02 GMTLow Dose CAR T Therapy Achieved High Remission Rates - EMJEMJ · Sun, 09 Aug 2026 15:03:11 GMTRiboX’s Circular RNA CAR-T IND Clearance Forces the Industry to Rethink Everything It Knows About Cell Therapy Trial Design - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sun, 09 Aug 2026 07:28:07 GMTFDA Clears IND for RiboX’s RXIM002, Circular RNA CAR-T for ITP - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sun, 09 Aug 2026 06:34:09 GMTScience Fiction Made Real: Kerry Rogers, MD, on How CAR T Works - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Sat, 08 Aug 2026 12:27:00 GMTWhat Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma - CancerNetworkCancerNetwork · Fri, 07 Aug 2026 22:04:53 GMTDr Cohen on Future Research Avenues for Cevostamab in R/R Myeloma - OncLiveOncLive · Fri, 07 Aug 2026 19:12:33 GMT